Heron Therapeutics (HRTX) Earnings Date & Reports

Key Takeaways

• Heron Therapeutics reported a net loss of $5.0 million for the third quarter of 2026, a sharp improvement from the $17.5 million net loss recorded a year earlier.
• Net product sales came in at $35.3 million, down from $38.2 million in the prior-year quarter and below analyst consensus expectations.
• Net loss per share was $0.03, narrowing meaningfully from a loss of $0.10 per share in the same period of 2025.
• Gross profit of $26.3 million was essentially flat year over year, supported by lower cost of product sales.
• Shares rose sharply in premarket trading following the release, reflecting an investor focus on the narrowed loss rather than the softer revenue line.
• For more details, explore Heron Therapeutics' Major News, Today's Price Move, Price Targets, and Forecast on Tickeron's dedicated pages.
• Looking for automated market insights? Discover Trending AI Robots to explore AI-driven trading strategies and ideas.

Earnings Context and Why It Matters

Heron Therapeutics is a commercial-stage biotechnology company focused on acute care and oncology therapies, anchored by products such as ZYNRELEF, APONVIE, and CINVANTI. Its third-quarter 2026 report carries added weight because the company has spent much of the year navigating competitive pressure in its oncology franchise while working to grow its acute care portfolio. Earlier in 2026, management withdrew its full-year guidance following a court decision that raised uncertainty around potential generic competition, making each quarterly print a key checkpoint for the durability of revenue and the trajectory of cash resources. Investors are watching whether cost discipline and narrowing losses can offset a declining top line.

Reported Results

For the third quarter ended September 30, 2026, Heron Therapeutics reported net product sales of $35.25 million, down from $38.21 million in the prior-year period. This figure came in below analyst consensus estimates. The company posted a net loss of $5.0 million, a substantial narrowing from the $17.5 million net loss recorded in the third quarter of 2025. Net loss per share, basic and diluted, was $0.03, compared with a loss of $0.10 per share in the year-ago quarter, and was roughly in line with the consensus estimate of a $0.03 loss.

Gross profit held steady at $26.3 million, supported by a decline in cost of product sales to $9.0 million from $11.9 million a year earlier. Total operating expenses decreased to $28.0 million from $30.4 million, driven by reductions across research and development, general and administrative, and sales and marketing spending. For the nine months ended September 30, 2026, net product sales totaled $107.6 million versus $114.3 million in the prior-year period, while the net loss was $18.6 million compared with $17.2 million a year ago.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, giving investors a streamlined way to identify setups that match their criteria. Explore the AI Screener to see how AI-driven filtering can support your research workflow.

Market Reaction and Investor Sentiment

Shares of Heron Therapeutics rose sharply in premarket trading following the release, a reaction that suggested investors weighed the significantly narrower net loss more heavily than the year-over-year decline in product sales. The improved bottom line, aided by disciplined cost control and lower operating expenses, offered a contrast to a revenue line that continues to face headwinds in the oncology segment. The stock has nonetheless been under sustained pressure over the past year, reflecting concerns about generic competition, the withdrawn full-year guidance, and a shrinking cash position. Sentiment around the quarter appeared focused on the company's ability to preserve cash and stabilize the business while strategic alternatives remain under review.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors should monitor whether Heron Therapeutics can sustain its narrowed losses even as net product sales trend lower. The acute care franchise, led by ZYNRELEF and APONVIE, has been the primary growth engine, while CINVANTI faces branded competition and the oncology segment has been declining. Sustaining acute care momentum will be central to offsetting those pressures.

Cash management and covenant compliance remain critical watch items. With full-year guidance withdrawn and strategic alternatives under consideration, the company's quarterly disclosures around cash, spending, and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) will carry outsized importance. Investors should also track any updates on the timing and potential impact of generic competition, which management has flagged as a key source of uncertainty.

Finally, watch for signals on expense discipline and gross margin trends. Lower cost of product sales supported gross profit this quarter, but sustaining that improvement will depend on product mix and inventory management. These factors, rather than headline revenue alone, are likely to shape how the market interprets Heron's progress in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations